Please enable JavaScript to continue using this application.

Compare $AKBA vs $RNAC | Chartloom

Compare

$AKBA vs $RNAC

Akebia Therapeutics Inc · Cartesian Therapeutics Inc

AKBA

Akebia Therapeutics Inc

RNAC

Cartesian Therapeutics Inc

Compare $AKBA vs $RNAC

Comparing Akebia Therapeutics Inc and Cartesian Therapeutics Inc

AKBAAkebia Therapeutics Inc

RNACCartesian Therapeutics Inc

AKBAAkebia Therapeutics Inc

Market cap

$215M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.35x

Rev growth (TTM)

7.5%

YTD performance

-48.3%

52W performance

-71.9%

FCF yield

13.7%

RNACCartesian Therapeutics Inc

Market cap

$207M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

473.62x

Rev growth (TTM)

-20.7%

YTD performance

4.4%

52W performance

-31.0%

FCF yield

-37.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKBA

RNAC

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

AKBA$215M

RNAC$207M

Enterprise Value

AKBA$252M

RNAC$113M

Price

AKBA$0.80

RNAC$7.06

P/E Ratio

AKBAN/A

RNACN/A

P/S Ratio

AKBA0.98x

RNAC140.34x

EV/Sales

AKBA1.15x

RNAC76.18x

EV/EBITDA

AKBA49.22x

RNAC0.00x

P/B Ratio

AKBA9.58x

RNAC296.12x

P/FCF Ratio

AKBA7.30x

RNACN/A

EV/FCF

AKBA8.54x

RNAC-1.43x

PEG Ratio

AKBAN/A

RNACN/A

Forward P/E (NTM)

AKBAN/A

RNACN/A

Forward P/S (NTM)

AKBA1.35x

RNAC473.62x

Revenue (TTM)

AKBA$219M

RNAC$1M

Revenue Growth (YoY)

AKBA7.5%

RNAC-20.7%

Forward Rev Growth

AKBA-33.0%

RNAC-14.0%

Gross Margin (TTM)

AKBA81.5%

RNAC0.0%

Operating Margin (TTM)

AKBA0.0%

RNAC0.0%

EBITDA Margin (TTM)

AKBA-1.9%

RNAC-6503.1%

Net Margin (TTM)

AKBA-13.5%

RNAC-10422.5%

FCF Margin (TTM)

AKBA13.4%

RNAC-5322.4%

Net Income (TTM)

AKBA$-30M

RNAC$-154M

FCF (TTM)

AKBA$29M

RNAC$-79M

EPS (TTM)

AKBA-$0.11

RNAC-$5.16

ROE (TTM)

AKBA-9374.0%

RNAC-321582.0%

ROA (TTM)

AKBA-817.0%

RNAC-4761.0%

ROIC (TTM)

AKBA-1321.0%

RNAC-321582.0%

Cash

AKBA$156M

RNAC$148M

Debt

AKBA$192M

RNAC$53M

Net Cash/Debt

AKBA$-37M

RNAC$95M

Current Ratio (TTM)

AKBA1.43x

RNAC7.48x

Quick Ratio (TTM)

AKBA1.31x

RNAC7.19x

Debt/Equity (TTM)

AKBA7.69x

RNAC0.28x

Debt/Assets (TTM)

AKBA0.0%

RNAC0.0%

Interest Coverage (TTM)

AKBAN/A

RNACN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

RNAC0.00x

Beta

AKBA0.20

RNAC0.74

52W Performance

AKBA-71.9%

RNAC-31.0%

YTD Performance

AKBA-48.3%

RNAC4.4%

% from 52W High

AKBA-75.0%

RNAC-35.9%

% from 52W Low

AKBA0.0%

RNAC26.0%

Asset Turnover (TTM)

AKBA0.60x

RNAC0.01x

FCF Yield (TTM)

AKBA13.7%

RNAC-37.9%

Earnings Yield (TTM)

AKBA-13.8%

RNAC-74.3%

Dividend Yield (TTM)

AKBAN/A

RNACN/A

Rule of 40

AKBA21.0

RNAC-5,343.1

EV/GP/RG

AKBAN/A

RNACN/A

Ticker research

View AKBA research View RNAC research

Metric	AKBA Akebia Therapeutics Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$215M	$207M
Enterprise Value	$252M	$113M
Price	$0.80	$7.06
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	140.34x
EV/Sales	1.15x	76.18x
EV/EBITDA	49.22x	0.00x
P/B Ratio	9.58x	296.12x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-1.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	473.62x
Revenue & Growth
Revenue (TTM)	$219M	$1M
Revenue Growth (YoY)	7.5%	-20.7%
Forward Rev Growth	-33.0%	-14.0%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-6503.1%
Net Margin (TTM)	-13.5%	-10422.5%
FCF Margin (TTM)	13.4%	-5322.4%
Net Income (TTM)	$-30M	$-154M
FCF (TTM)	$29M	$-79M
EPS (TTM)	-$0.11	-$5.16
ROE (TTM)	-9374.0%	-321582.0%
ROA (TTM)	-817.0%	-4761.0%
ROIC (TTM)	-1321.0%	-321582.0%
Financial Health
Cash	$156M	$148M
Debt	$192M	$53M
Net Cash/Debt	$-37M	$95M
Current Ratio (TTM)	1.43x	7.48x
Quick Ratio (TTM)	1.31x	7.19x
Debt/Equity (TTM)	7.69x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	0.74
52W Performance	-71.9%	-31.0%
YTD Performance	-48.3%	4.4%
% from 52W High	-75.0%	-35.9%
% from 52W Low	0.0%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.01x
FCF Yield (TTM)	13.7%	-37.9%
Earnings Yield (TTM)	-13.8%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View RNAC research

Valuation

P/S Ratio

AKBA

0.98x

RNAC

140.34x

EV/FCF

RNAC

-1.43x

AKBA

8.54x

Growth & revenue

Revenue Growth TTM

AKBA

7.5%

RNAC

-20.7%

Forward Revenue Growth

RNAC

-14.0%

AKBA

-33.0%

Profitability & performance

Gross Margin

AKBA

81.5%

RNAC

0.0%

ROE

AKBA

-9374.0%

RNAC

-321582.0%

FCF Yield %

AKBA

13.7%

RNAC

-37.9%

52-Week Performance

RNAC

-31.0%

AKBA

-71.9%

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

AKBA$215M

RNAC$207M

Enterprise Value

AKBA$252M

RNAC$113M

Price

AKBA$0.80

RNAC$7.06

P/E Ratio

AKBAN/A

RNACN/A

P/S Ratio

AKBA0.98x

RNAC140.34x

EV/Sales

AKBA1.15x

RNAC76.18x

EV/EBITDA

AKBA49.22x

RNAC0.00x

P/B Ratio

AKBA9.58x

RNAC296.12x

P/FCF Ratio

AKBA7.30x

RNACN/A

EV/FCF

AKBA8.54x

RNAC-1.43x

PEG Ratio

AKBAN/A

RNACN/A

Forward P/E (NTM)

AKBAN/A

RNACN/A

Forward P/S (NTM)

AKBA1.35x

RNAC473.62x

Revenue (TTM)

AKBA$219M

RNAC$1M

Revenue Growth (YoY)

AKBA7.5%

RNAC-20.7%

Forward Rev Growth

AKBA-33.0%

RNAC-14.0%

Gross Margin (TTM)

AKBA81.5%

RNAC0.0%

Operating Margin (TTM)

AKBA0.0%

RNAC0.0%

EBITDA Margin (TTM)

AKBA-1.9%

RNAC-6503.1%

Net Margin (TTM)

AKBA-13.5%

RNAC-10422.5%

FCF Margin (TTM)

AKBA13.4%

RNAC-5322.4%

Net Income (TTM)

AKBA$-30M

RNAC$-154M

FCF (TTM)

AKBA$29M

RNAC$-79M

EPS (TTM)

AKBA-$0.11

RNAC-$5.16

ROE (TTM)

AKBA-9374.0%

RNAC-321582.0%

ROA (TTM)

AKBA-817.0%

RNAC-4761.0%

ROIC (TTM)

AKBA-1321.0%

RNAC-321582.0%

Cash

AKBA$156M

RNAC$148M

Debt

AKBA$192M

RNAC$53M

Net Cash/Debt

AKBA$-37M

RNAC$95M

Current Ratio (TTM)

AKBA1.43x

RNAC7.48x

Quick Ratio (TTM)

AKBA1.31x

RNAC7.19x

Debt/Equity (TTM)

AKBA7.69x

RNAC0.28x

Debt/Assets (TTM)

AKBA0.0%

RNAC0.0%

Interest Coverage (TTM)

AKBAN/A

RNACN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

RNAC0.00x

Beta

AKBA0.20

RNAC0.74

52W Performance

AKBA-71.9%

RNAC-31.0%

YTD Performance

AKBA-48.3%

RNAC4.4%

% from 52W High

AKBA-75.0%

RNAC-35.9%

% from 52W Low

AKBA0.0%

RNAC26.0%

Asset Turnover (TTM)

AKBA0.60x

RNAC0.01x

FCF Yield (TTM)

AKBA13.7%

RNAC-37.9%

Earnings Yield (TTM)

AKBA-13.8%

RNAC-74.3%

Dividend Yield (TTM)

AKBAN/A

RNACN/A

Rule of 40

AKBA21.0

RNAC-5,343.1

EV/GP/RG

AKBAN/A

RNACN/A

Ticker research

View AKBA research View RNAC research

Metric	AKBA Akebia Therapeutics Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$215M	$207M
Enterprise Value	$252M	$113M
Price	$0.80	$7.06
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	140.34x
EV/Sales	1.15x	76.18x
EV/EBITDA	49.22x	0.00x
P/B Ratio	9.58x	296.12x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-1.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	473.62x
Revenue & Growth
Revenue (TTM)	$219M	$1M
Revenue Growth (YoY)	7.5%	-20.7%
Forward Rev Growth	-33.0%	-14.0%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-6503.1%
Net Margin (TTM)	-13.5%	-10422.5%
FCF Margin (TTM)	13.4%	-5322.4%
Net Income (TTM)	$-30M	$-154M
FCF (TTM)	$29M	$-79M
EPS (TTM)	-$0.11	-$5.16
ROE (TTM)	-9374.0%	-321582.0%
ROA (TTM)	-817.0%	-4761.0%
ROIC (TTM)	-1321.0%	-321582.0%
Financial Health
Cash	$156M	$148M
Debt	$192M	$53M
Net Cash/Debt	$-37M	$95M
Current Ratio (TTM)	1.43x	7.48x
Quick Ratio (TTM)	1.31x	7.19x
Debt/Equity (TTM)	7.69x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	0.74
52W Performance	-71.9%	-31.0%
YTD Performance	-48.3%	4.4%
% from 52W High	-75.0%	-35.9%
% from 52W Low	0.0%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.01x
FCF Yield (TTM)	13.7%	-37.9%
Earnings Yield (TTM)	-13.8%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View RNAC research